nodes	percent_of_prediction	percent_of_DWPC	metapath
Silodosin—ABCB1—hematologic cancer	0.15	1	CbGaD
Silodosin—UGT2B7—Epirubicin—hematologic cancer	0.0556	0.105	CbGbCtD
Silodosin—ABCB1—Lenalidomide—hematologic cancer	0.033	0.0625	CbGbCtD
Silodosin—CYP3A4—Bexarotene—hematologic cancer	0.0198	0.0374	CbGbCtD
Silodosin—ABCB1—Daunorubicin—hematologic cancer	0.0194	0.0366	CbGbCtD
Silodosin—ABCB1—Alitretinoin—hematologic cancer	0.019	0.0359	CbGbCtD
Silodosin—CYP3A4—Lomustine—hematologic cancer	0.0184	0.0348	CbGbCtD
Silodosin—CYP3A4—Busulfan—hematologic cancer	0.0184	0.0348	CbGbCtD
Silodosin—CYP3A4—Thiotepa—hematologic cancer	0.0164	0.031	CbGbCtD
Silodosin—ABCB1—Imatinib—hematologic cancer	0.0148	0.0281	CbGbCtD
Silodosin—ABCB1—Nilotinib—hematologic cancer	0.0135	0.0255	CbGbCtD
Silodosin—ABCB1—Vinorelbine—hematologic cancer	0.0134	0.0253	CbGbCtD
Silodosin—CYP3A4—Methoxsalen—hematologic cancer	0.0128	0.0241	CbGbCtD
Silodosin—CYP3A4—Bortezomib—hematologic cancer	0.0121	0.0229	CbGbCtD
Silodosin—ABCB1—Dasatinib—hematologic cancer	0.0119	0.0225	CbGbCtD
Silodosin—ABCB1—Mitoxantrone—hematologic cancer	0.0118	0.0223	CbGbCtD
Silodosin—CYP3A4—Daunorubicin—hematologic cancer	0.0116	0.0219	CbGbCtD
Silodosin—ABCB1—Betamethasone—hematologic cancer	0.0105	0.0198	CbGbCtD
Silodosin—ABCB1—Gemcitabine—hematologic cancer	0.0104	0.0197	CbGbCtD
Silodosin—ABCB1—Prednisolone—hematologic cancer	0.0104	0.0196	CbGbCtD
Silodosin—CYP3A4—Cytarabine—hematologic cancer	0.0102	0.0194	CbGbCtD
Silodosin—CYP3A4—Teniposide—hematologic cancer	0.0101	0.0191	CbGbCtD
Silodosin—ABCB1—Prednisone—hematologic cancer	0.00978	0.0185	CbGbCtD
Silodosin—CYP3A4—Ifosfamide—hematologic cancer	0.00931	0.0176	CbGbCtD
Silodosin—ABCB1—Irinotecan—hematologic cancer	0.00927	0.0175	CbGbCtD
Silodosin—CYP3A4—Imatinib—hematologic cancer	0.00889	0.0168	CbGbCtD
Silodosin—CYP3A4—Ruxolitinib—hematologic cancer	0.00837	0.0158	CbGbCtD
Silodosin—ABCB1—Vinblastine—hematologic cancer	0.00824	0.0156	CbGbCtD
Silodosin—ABCB1—Vincristine—hematologic cancer	0.0081	0.0153	CbGbCtD
Silodosin—CYP3A4—Nilotinib—hematologic cancer	0.00808	0.0153	CbGbCtD
Silodosin—CYP3A4—Vinorelbine—hematologic cancer	0.00801	0.0151	CbGbCtD
Silodosin—ABCB1—Cisplatin—hematologic cancer	0.00756	0.0143	CbGbCtD
Silodosin—ABCB1—Etoposide—hematologic cancer	0.00742	0.014	CbGbCtD
Silodosin—CYP3A4—Triamcinolone—hematologic cancer	0.00733	0.0139	CbGbCtD
Silodosin—CYP3A4—Dasatinib—hematologic cancer	0.00714	0.0135	CbGbCtD
Silodosin—CYP3A4—Mitoxantrone—hematologic cancer	0.00705	0.0133	CbGbCtD
Silodosin—CYP3A4—Betamethasone—hematologic cancer	0.00629	0.0119	CbGbCtD
Silodosin—CYP3A4—Prednisolone—hematologic cancer	0.0062	0.0117	CbGbCtD
Silodosin—ABCB1—Dexamethasone—hematologic cancer	0.0061	0.0115	CbGbCtD
Silodosin—CYP3A4—Prednisone—hematologic cancer	0.00586	0.0111	CbGbCtD
Silodosin—CYP3A4—Irinotecan—hematologic cancer	0.00555	0.0105	CbGbCtD
Silodosin—ABCB1—Doxorubicin—hematologic cancer	0.00506	0.00957	CbGbCtD
Silodosin—CYP3A4—Vinblastine—hematologic cancer	0.00494	0.00933	CbGbCtD
Silodosin—ABCB1—Methotrexate—hematologic cancer	0.00491	0.00927	CbGbCtD
Silodosin—CYP3A4—Vincristine—hematologic cancer	0.00485	0.00918	CbGbCtD
Silodosin—CYP3A4—Etoposide—hematologic cancer	0.00445	0.00841	CbGbCtD
Silodosin—CYP3A4—Dexamethasone—hematologic cancer	0.00366	0.00691	CbGbCtD
Silodosin—ABCB4—hematopoietic system—hematologic cancer	0.00344	0.252	CbGeAlD
Silodosin—CYP3A4—Doxorubicin—hematologic cancer	0.00303	0.00574	CbGbCtD
Silodosin—ABCB4—blood—hematologic cancer	0.00228	0.167	CbGeAlD
Silodosin—ABCB4—testis—hematologic cancer	0.00189	0.138	CbGeAlD
Silodosin—ABCB4—lymph node—hematologic cancer	0.00137	0.1	CbGeAlD
Silodosin—UGT2B7—testis—hematologic cancer	0.000965	0.0708	CbGeAlD
Silodosin—ADRA1A—hematopoietic system—hematologic cancer	0.000802	0.0588	CbGeAlD
Silodosin—ADRA1A—blood—hematologic cancer	0.000531	0.039	CbGeAlD
Silodosin—CYP3A4—hematopoietic system—hematologic cancer	0.00048	0.0352	CbGeAlD
Silodosin—ABCB1—hematopoietic system—hematologic cancer	0.00034	0.0249	CbGeAlD
Silodosin—CYP3A4—blood—hematologic cancer	0.000318	0.0233	CbGeAlD
Silodosin—ABCB1—gonad—hematologic cancer	0.000258	0.019	CbGeAlD
Silodosin—ABCB1—blood—hematologic cancer	0.000225	0.0165	CbGeAlD
Silodosin—ABCB1—bone marrow—hematologic cancer	0.000218	0.016	CbGeAlD
Silodosin—ABCB1—lung—hematologic cancer	0.000197	0.0145	CbGeAlD
Silodosin—ABCB1—testis—hematologic cancer	0.000186	0.0137	CbGeAlD
Silodosin—ABCB1—lymph node—hematologic cancer	0.000135	0.0099	CbGeAlD
Silodosin—Hypotension—Etoposide—hematologic cancer	0.000109	0.000524	CcSEcCtD
Silodosin—Rash—Bleomycin—hematologic cancer	0.000109	0.000524	CcSEcCtD
Silodosin—Dermatitis—Bleomycin—hematologic cancer	0.000109	0.000523	CcSEcCtD
Silodosin—Asthenia—Carmustine—hematologic cancer	0.000109	0.00052	CcSEcCtD
Silodosin—Dry mouth—Triamcinolone—hematologic cancer	0.000108	0.000519	CcSEcCtD
Silodosin—Diarrhoea—Thalidomide—hematologic cancer	0.000108	0.000517	CcSEcCtD
Silodosin—Dizziness—Thiotepa—hematologic cancer	0.000108	0.000516	CcSEcCtD
Silodosin—Asthenia—Alitretinoin—hematologic cancer	0.000108	0.000516	CcSEcCtD
Silodosin—Rash—Vinorelbine—hematologic cancer	0.000108	0.000516	CcSEcCtD
Silodosin—Dermatitis—Vinorelbine—hematologic cancer	0.000108	0.000515	CcSEcCtD
Silodosin—Angiopathy—Prednisone—hematologic cancer	0.000107	0.000513	CcSEcCtD
Silodosin—Headache—Vinorelbine—hematologic cancer	0.000107	0.000512	CcSEcCtD
Silodosin—Immune system disorder—Prednisone—hematologic cancer	0.000107	0.000511	CcSEcCtD
Silodosin—Asthenia—Ifosfamide—hematologic cancer	0.000106	0.00051	CcSEcCtD
Silodosin—Pruritus—Alitretinoin—hematologic cancer	0.000106	0.000508	CcSEcCtD
Silodosin—Syncope—Betamethasone—hematologic cancer	0.000106	0.000507	CcSEcCtD
Silodosin—Syncope—Dexamethasone—hematologic cancer	0.000106	0.000507	CcSEcCtD
Silodosin—Pruritus—Ifosfamide—hematologic cancer	0.000105	0.000502	CcSEcCtD
Silodosin—Shock—Triamcinolone—hematologic cancer	0.000105	0.000501	CcSEcCtD
Silodosin—Insomnia—Prednisolone—hematologic cancer	0.000104	0.0005	CcSEcCtD
Silodosin—Dizziness—Thalidomide—hematologic cancer	0.000104	0.000499	CcSEcCtD
Silodosin—Hepatobiliary disease—Methotrexate—hematologic cancer	0.000104	0.000498	CcSEcCtD
Silodosin—Nausea—Bortezomib—hematologic cancer	0.000104	0.000497	CcSEcCtD
Silodosin—Loss of consciousness—Dexamethasone—hematologic cancer	0.000104	0.000497	CcSEcCtD
Silodosin—Loss of consciousness—Betamethasone—hematologic cancer	0.000104	0.000497	CcSEcCtD
Silodosin—Asthenia—Vincristine—hematologic cancer	0.000104	0.000497	CcSEcCtD
Silodosin—Tachycardia—Triamcinolone—hematologic cancer	0.000104	0.000497	CcSEcCtD
Silodosin—Diarrhoea—Carmustine—hematologic cancer	0.000104	0.000496	CcSEcCtD
Silodosin—Mental disorder—Prednisone—hematologic cancer	0.000103	0.000496	CcSEcCtD
Silodosin—Nausea—Bleomycin—hematologic cancer	0.000103	0.000494	CcSEcCtD
Silodosin—Rash—Thiotepa—hematologic cancer	0.000103	0.000492	CcSEcCtD
Silodosin—Dermatitis—Thiotepa—hematologic cancer	0.000103	0.000492	CcSEcCtD
Silodosin—Diarrhoea—Alitretinoin—hematologic cancer	0.000103	0.000492	CcSEcCtD
Silodosin—Headache—Thiotepa—hematologic cancer	0.000102	0.000489	CcSEcCtD
Silodosin—Diarrhoea—Ifosfamide—hematologic cancer	0.000101	0.000486	CcSEcCtD
Silodosin—Nausea—Vinorelbine—hematologic cancer	0.000101	0.000486	CcSEcCtD
Silodosin—Gastrointestinal disorder—Etoposide—hematologic cancer	0.000101	0.000484	CcSEcCtD
Silodosin—Asthenia—Mitoxantrone—hematologic cancer	0.000101	0.000484	CcSEcCtD
Silodosin—Asthenia—Irinotecan—hematologic cancer	0.000101	0.000484	CcSEcCtD
Silodosin—Jaundice—Epirubicin—hematologic cancer	0.0001	0.000481	CcSEcCtD
Silodosin—Dizziness—Carmustine—hematologic cancer	0.0001	0.00048	CcSEcCtD
Silodosin—Rash—Thalidomide—hematologic cancer	9.94e-05	0.000476	CcSEcCtD
Silodosin—Dermatitis—Thalidomide—hematologic cancer	9.93e-05	0.000476	CcSEcCtD
Silodosin—Dizziness—Alitretinoin—hematologic cancer	9.92e-05	0.000475	CcSEcCtD
Silodosin—Diarrhoea—Vincristine—hematologic cancer	9.89e-05	0.000474	CcSEcCtD
Silodosin—Headache—Thalidomide—hematologic cancer	9.88e-05	0.000473	CcSEcCtD
Silodosin—Asthenia—Gemcitabine—hematologic cancer	9.84e-05	0.000471	CcSEcCtD
Silodosin—Dizziness—Ifosfamide—hematologic cancer	9.8e-05	0.00047	CcSEcCtD
Silodosin—Hepatobiliary disease—Epirubicin—hematologic cancer	9.73e-05	0.000466	CcSEcCtD
Silodosin—Pruritus—Gemcitabine—hematologic cancer	9.7e-05	0.000465	CcSEcCtD
Silodosin—Nausea—Thiotepa—hematologic cancer	9.68e-05	0.000464	CcSEcCtD
Silodosin—Sinusitis—Epirubicin—hematologic cancer	9.66e-05	0.000463	CcSEcCtD
Silodosin—Diarrhoea—Irinotecan—hematologic cancer	9.63e-05	0.000461	CcSEcCtD
Silodosin—Diarrhoea—Mitoxantrone—hematologic cancer	9.63e-05	0.000461	CcSEcCtD
Silodosin—Insomnia—Triamcinolone—hematologic cancer	9.61e-05	0.00046	CcSEcCtD
Silodosin—Gastrointestinal pain—Etoposide—hematologic cancer	9.58e-05	0.000459	CcSEcCtD
Silodosin—Dizziness—Vincristine—hematologic cancer	9.56e-05	0.000458	CcSEcCtD
Silodosin—Rash—Carmustine—hematologic cancer	9.55e-05	0.000457	CcSEcCtD
Silodosin—Dermatitis—Carmustine—hematologic cancer	9.54e-05	0.000457	CcSEcCtD
Silodosin—Headache—Carmustine—hematologic cancer	9.49e-05	0.000454	CcSEcCtD
Silodosin—Shock—Dexamethasone—hematologic cancer	9.48e-05	0.000454	CcSEcCtD
Silodosin—Shock—Betamethasone—hematologic cancer	9.48e-05	0.000454	CcSEcCtD
Silodosin—Rash—Alitretinoin—hematologic cancer	9.46e-05	0.000453	CcSEcCtD
Silodosin—Nervous system disorder—Dexamethasone—hematologic cancer	9.45e-05	0.000453	CcSEcCtD
Silodosin—Nervous system disorder—Betamethasone—hematologic cancer	9.45e-05	0.000453	CcSEcCtD
Silodosin—Dermatitis—Alitretinoin—hematologic cancer	9.45e-05	0.000453	CcSEcCtD
Silodosin—Tachycardia—Betamethasone—hematologic cancer	9.41e-05	0.000451	CcSEcCtD
Silodosin—Tachycardia—Dexamethasone—hematologic cancer	9.41e-05	0.000451	CcSEcCtD
Silodosin—Headache—Alitretinoin—hematologic cancer	9.4e-05	0.00045	CcSEcCtD
Silodosin—Diarrhoea—Gemcitabine—hematologic cancer	9.38e-05	0.000449	CcSEcCtD
Silodosin—Nausea—Thalidomide—hematologic cancer	9.37e-05	0.000449	CcSEcCtD
Silodosin—Rash—Ifosfamide—hematologic cancer	9.35e-05	0.000448	CcSEcCtD
Silodosin—Dermatitis—Ifosfamide—hematologic cancer	9.34e-05	0.000447	CcSEcCtD
Silodosin—Dizziness—Irinotecan—hematologic cancer	9.31e-05	0.000446	CcSEcCtD
Silodosin—Urticaria—Etoposide—hematologic cancer	9.3e-05	0.000446	CcSEcCtD
Silodosin—Jaundice—Doxorubicin—hematologic cancer	9.28e-05	0.000445	CcSEcCtD
Silodosin—Abdominal pain—Etoposide—hematologic cancer	9.26e-05	0.000443	CcSEcCtD
Silodosin—Syncope—Prednisone—hematologic cancer	9.22e-05	0.000442	CcSEcCtD
Silodosin—Urticaria—Prednisolone—hematologic cancer	9.18e-05	0.00044	CcSEcCtD
Silodosin—Asthenia—Cisplatin—hematologic cancer	9.17e-05	0.000439	CcSEcCtD
Silodosin—Cardiac disorder—Methotrexate—hematologic cancer	9.16e-05	0.000439	CcSEcCtD
Silodosin—Rash—Vincristine—hematologic cancer	9.11e-05	0.000437	CcSEcCtD
Silodosin—Dermatitis—Vincristine—hematologic cancer	9.11e-05	0.000436	CcSEcCtD
Silodosin—Headache—Vincristine—hematologic cancer	9.06e-05	0.000434	CcSEcCtD
Silodosin—Loss of consciousness—Prednisone—hematologic cancer	9.04e-05	0.000433	CcSEcCtD
Silodosin—Hepatobiliary disease—Doxorubicin—hematologic cancer	9.01e-05	0.000431	CcSEcCtD
Silodosin—Hypotension—Betamethasone—hematologic cancer	9.01e-05	0.000431	CcSEcCtD
Silodosin—Hypotension—Dexamethasone—hematologic cancer	9.01e-05	0.000431	CcSEcCtD
Silodosin—Nausea—Carmustine—hematologic cancer	9e-05	0.000431	CcSEcCtD
Silodosin—Angiopathy—Methotrexate—hematologic cancer	8.96e-05	0.000429	CcSEcCtD
Silodosin—Sinusitis—Doxorubicin—hematologic cancer	8.93e-05	0.000428	CcSEcCtD
Silodosin—Immune system disorder—Methotrexate—hematologic cancer	8.92e-05	0.000427	CcSEcCtD
Silodosin—Nausea—Alitretinoin—hematologic cancer	8.91e-05	0.000427	CcSEcCtD
Silodosin—Mediastinal disorder—Methotrexate—hematologic cancer	8.9e-05	0.000426	CcSEcCtD
Silodosin—Rash—Mitoxantrone—hematologic cancer	8.88e-05	0.000425	CcSEcCtD
Silodosin—Rash—Irinotecan—hematologic cancer	8.88e-05	0.000425	CcSEcCtD
Silodosin—Dermatitis—Irinotecan—hematologic cancer	8.87e-05	0.000425	CcSEcCtD
Silodosin—Dermatitis—Mitoxantrone—hematologic cancer	8.87e-05	0.000425	CcSEcCtD
Silodosin—Headache—Irinotecan—hematologic cancer	8.82e-05	0.000422	CcSEcCtD
Silodosin—Headache—Mitoxantrone—hematologic cancer	8.82e-05	0.000422	CcSEcCtD
Silodosin—Nausea—Ifosfamide—hematologic cancer	8.81e-05	0.000422	CcSEcCtD
Silodosin—Diarrhoea—Cisplatin—hematologic cancer	8.75e-05	0.000419	CcSEcCtD
Silodosin—Insomnia—Dexamethasone—hematologic cancer	8.72e-05	0.000418	CcSEcCtD
Silodosin—Insomnia—Betamethasone—hematologic cancer	8.72e-05	0.000418	CcSEcCtD
Silodosin—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	8.7e-05	0.000416	CcSEcCtD
Silodosin—Mental disorder—Methotrexate—hematologic cancer	8.65e-05	0.000414	CcSEcCtD
Silodosin—Rash—Gemcitabine—hematologic cancer	8.65e-05	0.000414	CcSEcCtD
Silodosin—Dermatitis—Gemcitabine—hematologic cancer	8.64e-05	0.000414	CcSEcCtD
Silodosin—Headache—Gemcitabine—hematologic cancer	8.59e-05	0.000412	CcSEcCtD
Silodosin—Nausea—Vincristine—hematologic cancer	8.59e-05	0.000411	CcSEcCtD
Silodosin—Cardiac disorder—Epirubicin—hematologic cancer	8.58e-05	0.000411	CcSEcCtD
Silodosin—Urticaria—Triamcinolone—hematologic cancer	8.44e-05	0.000404	CcSEcCtD
Silodosin—Asthenia—Etoposide—hematologic cancer	8.4e-05	0.000402	CcSEcCtD
Silodosin—Angiopathy—Epirubicin—hematologic cancer	8.38e-05	0.000402	CcSEcCtD
Silodosin—Nausea—Irinotecan—hematologic cancer	8.36e-05	0.000401	CcSEcCtD
Silodosin—Nausea—Mitoxantrone—hematologic cancer	8.36e-05	0.000401	CcSEcCtD
Silodosin—Immune system disorder—Epirubicin—hematologic cancer	8.35e-05	0.0004	CcSEcCtD
Silodosin—Mediastinal disorder—Epirubicin—hematologic cancer	8.33e-05	0.000399	CcSEcCtD
Silodosin—Gastrointestinal disorder—Betamethasone—hematologic cancer	8.32e-05	0.000399	CcSEcCtD
Silodosin—Gastrointestinal disorder—Dexamethasone—hematologic cancer	8.32e-05	0.000399	CcSEcCtD
Silodosin—Pruritus—Etoposide—hematologic cancer	8.29e-05	0.000397	CcSEcCtD
Silodosin—Shock—Prednisone—hematologic cancer	8.26e-05	0.000396	CcSEcCtD
Silodosin—Nervous system disorder—Prednisone—hematologic cancer	8.23e-05	0.000394	CcSEcCtD
Silodosin—Tachycardia—Prednisone—hematologic cancer	8.19e-05	0.000392	CcSEcCtD
Silodosin—Skin disorder—Prednisone—hematologic cancer	8.15e-05	0.000391	CcSEcCtD
Silodosin—Nausea—Gemcitabine—hematologic cancer	8.15e-05	0.00039	CcSEcCtD
Silodosin—Mental disorder—Epirubicin—hematologic cancer	8.09e-05	0.000388	CcSEcCtD
Silodosin—Rash—Cisplatin—hematologic cancer	8.06e-05	0.000386	CcSEcCtD
Silodosin—Dermatitis—Cisplatin—hematologic cancer	8.05e-05	0.000386	CcSEcCtD
Silodosin—Diarrhoea—Etoposide—hematologic cancer	8.01e-05	0.000384	CcSEcCtD
Silodosin—Cardiac disorder—Doxorubicin—hematologic cancer	7.93e-05	0.00038	CcSEcCtD
Silodosin—Gastrointestinal pain—Dexamethasone—hematologic cancer	7.88e-05	0.000378	CcSEcCtD
Silodosin—Gastrointestinal pain—Betamethasone—hematologic cancer	7.88e-05	0.000378	CcSEcCtD
Silodosin—Angiopathy—Doxorubicin—hematologic cancer	7.76e-05	0.000372	CcSEcCtD
Silodosin—Dizziness—Etoposide—hematologic cancer	7.74e-05	0.000371	CcSEcCtD
Silodosin—Immune system disorder—Doxorubicin—hematologic cancer	7.72e-05	0.00037	CcSEcCtD
Silodosin—Mediastinal disorder—Doxorubicin—hematologic cancer	7.7e-05	0.000369	CcSEcCtD
Silodosin—Urticaria—Betamethasone—hematologic cancer	7.66e-05	0.000367	CcSEcCtD
Silodosin—Urticaria—Dexamethasone—hematologic cancer	7.66e-05	0.000367	CcSEcCtD
Silodosin—Dizziness—Prednisolone—hematologic cancer	7.64e-05	0.000366	CcSEcCtD
Silodosin—Asthenia—Triamcinolone—hematologic cancer	7.62e-05	0.000365	CcSEcCtD
Silodosin—Abdominal pain—Dexamethasone—hematologic cancer	7.62e-05	0.000365	CcSEcCtD
Silodosin—Abdominal pain—Betamethasone—hematologic cancer	7.62e-05	0.000365	CcSEcCtD
Silodosin—Nausea—Cisplatin—hematologic cancer	7.59e-05	0.000364	CcSEcCtD
Silodosin—Insomnia—Prednisone—hematologic cancer	7.59e-05	0.000364	CcSEcCtD
Silodosin—Pruritus—Triamcinolone—hematologic cancer	7.51e-05	0.00036	CcSEcCtD
Silodosin—Mental disorder—Doxorubicin—hematologic cancer	7.49e-05	0.000359	CcSEcCtD
Silodosin—Rash—Etoposide—hematologic cancer	7.38e-05	0.000354	CcSEcCtD
Silodosin—Dermatitis—Etoposide—hematologic cancer	7.38e-05	0.000353	CcSEcCtD
Silodosin—Headache—Etoposide—hematologic cancer	7.34e-05	0.000351	CcSEcCtD
Silodosin—Rash—Prednisolone—hematologic cancer	7.28e-05	0.000349	CcSEcCtD
Silodosin—Dermatitis—Prednisolone—hematologic cancer	7.28e-05	0.000349	CcSEcCtD
Silodosin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	7.27e-05	0.000348	CcSEcCtD
Silodosin—Headache—Prednisolone—hematologic cancer	7.24e-05	0.000347	CcSEcCtD
Silodosin—Syncope—Epirubicin—hematologic cancer	7.21e-05	0.000346	CcSEcCtD
Silodosin—Palpitations—Epirubicin—hematologic cancer	7.11e-05	0.00034	CcSEcCtD
Silodosin—Loss of consciousness—Epirubicin—hematologic cancer	7.07e-05	0.000339	CcSEcCtD
Silodosin—Dizziness—Triamcinolone—hematologic cancer	7.02e-05	0.000336	CcSEcCtD
Silodosin—Nausea—Etoposide—hematologic cancer	6.96e-05	0.000333	CcSEcCtD
Silodosin—Asthenia—Betamethasone—hematologic cancer	6.91e-05	0.000331	CcSEcCtD
Silodosin—Asthenia—Dexamethasone—hematologic cancer	6.91e-05	0.000331	CcSEcCtD
Silodosin—Nervous system disorder—Methotrexate—hematologic cancer	6.88e-05	0.00033	CcSEcCtD
Silodosin—Gastrointestinal pain—Prednisone—hematologic cancer	6.86e-05	0.000329	CcSEcCtD
Silodosin—Nausea—Prednisolone—hematologic cancer	6.86e-05	0.000329	CcSEcCtD
Silodosin—Pruritus—Dexamethasone—hematologic cancer	6.82e-05	0.000327	CcSEcCtD
Silodosin—Pruritus—Betamethasone—hematologic cancer	6.82e-05	0.000327	CcSEcCtD
Silodosin—Skin disorder—Methotrexate—hematologic cancer	6.81e-05	0.000326	CcSEcCtD
Silodosin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	6.8e-05	0.000326	CcSEcCtD
Silodosin—Rash—Triamcinolone—hematologic cancer	6.7e-05	0.000321	CcSEcCtD
Silodosin—Dry mouth—Epirubicin—hematologic cancer	6.7e-05	0.000321	CcSEcCtD
Silodosin—Dermatitis—Triamcinolone—hematologic cancer	6.69e-05	0.000321	CcSEcCtD
Silodosin—Syncope—Doxorubicin—hematologic cancer	6.67e-05	0.00032	CcSEcCtD
Silodosin—Urticaria—Prednisone—hematologic cancer	6.67e-05	0.000319	CcSEcCtD
Silodosin—Headache—Triamcinolone—hematologic cancer	6.65e-05	0.000319	CcSEcCtD
Silodosin—Abdominal pain—Prednisone—hematologic cancer	6.63e-05	0.000318	CcSEcCtD
Silodosin—Diarrhoea—Betamethasone—hematologic cancer	6.59e-05	0.000316	CcSEcCtD
Silodosin—Diarrhoea—Dexamethasone—hematologic cancer	6.59e-05	0.000316	CcSEcCtD
Silodosin—Palpitations—Doxorubicin—hematologic cancer	6.58e-05	0.000315	CcSEcCtD
Silodosin—Hypotension—Methotrexate—hematologic cancer	6.55e-05	0.000314	CcSEcCtD
Silodosin—Loss of consciousness—Doxorubicin—hematologic cancer	6.54e-05	0.000313	CcSEcCtD
Silodosin—Shock—Epirubicin—hematologic cancer	6.46e-05	0.000309	CcSEcCtD
Silodosin—Nervous system disorder—Epirubicin—hematologic cancer	6.44e-05	0.000308	CcSEcCtD
Silodosin—Tachycardia—Epirubicin—hematologic cancer	6.41e-05	0.000307	CcSEcCtD
Silodosin—Skin disorder—Epirubicin—hematologic cancer	6.38e-05	0.000305	CcSEcCtD
Silodosin—Dizziness—Dexamethasone—hematologic cancer	6.37e-05	0.000305	CcSEcCtD
Silodosin—Dizziness—Betamethasone—hematologic cancer	6.37e-05	0.000305	CcSEcCtD
Silodosin—Insomnia—Methotrexate—hematologic cancer	6.34e-05	0.000304	CcSEcCtD
Silodosin—Nausea—Triamcinolone—hematologic cancer	6.31e-05	0.000302	CcSEcCtD
Silodosin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	6.29e-05	0.000301	CcSEcCtD
Silodosin—Dry mouth—Doxorubicin—hematologic cancer	6.2e-05	0.000297	CcSEcCtD
Silodosin—Hypotension—Epirubicin—hematologic cancer	6.13e-05	0.000294	CcSEcCtD
Silodosin—Rash—Betamethasone—hematologic cancer	6.08e-05	0.000291	CcSEcCtD
Silodosin—Rash—Dexamethasone—hematologic cancer	6.08e-05	0.000291	CcSEcCtD
Silodosin—Dermatitis—Betamethasone—hematologic cancer	6.07e-05	0.000291	CcSEcCtD
Silodosin—Dermatitis—Dexamethasone—hematologic cancer	6.07e-05	0.000291	CcSEcCtD
Silodosin—Gastrointestinal disorder—Methotrexate—hematologic cancer	6.06e-05	0.00029	CcSEcCtD
Silodosin—Headache—Betamethasone—hematologic cancer	6.04e-05	0.000289	CcSEcCtD
Silodosin—Headache—Dexamethasone—hematologic cancer	6.04e-05	0.000289	CcSEcCtD
Silodosin—Asthenia—Prednisone—hematologic cancer	6.02e-05	0.000288	CcSEcCtD
Silodosin—Shock—Doxorubicin—hematologic cancer	5.98e-05	0.000286	CcSEcCtD
Silodosin—Nervous system disorder—Doxorubicin—hematologic cancer	5.96e-05	0.000285	CcSEcCtD
Silodosin—Pruritus—Prednisone—hematologic cancer	5.94e-05	0.000284	CcSEcCtD
Silodosin—Insomnia—Epirubicin—hematologic cancer	5.94e-05	0.000284	CcSEcCtD
Silodosin—Tachycardia—Doxorubicin—hematologic cancer	5.93e-05	0.000284	CcSEcCtD
Silodosin—Skin disorder—Doxorubicin—hematologic cancer	5.9e-05	0.000283	CcSEcCtD
Silodosin—Diarrhoea—Prednisone—hematologic cancer	5.74e-05	0.000275	CcSEcCtD
Silodosin—Gastrointestinal pain—Methotrexate—hematologic cancer	5.74e-05	0.000275	CcSEcCtD
Silodosin—Nausea—Betamethasone—hematologic cancer	5.72e-05	0.000274	CcSEcCtD
Silodosin—Nausea—Dexamethasone—hematologic cancer	5.72e-05	0.000274	CcSEcCtD
Silodosin—Hypotension—Doxorubicin—hematologic cancer	5.68e-05	0.000272	CcSEcCtD
Silodosin—Gastrointestinal disorder—Epirubicin—hematologic cancer	5.67e-05	0.000271	CcSEcCtD
Silodosin—Urticaria—Methotrexate—hematologic cancer	5.57e-05	0.000267	CcSEcCtD
Silodosin—Dizziness—Prednisone—hematologic cancer	5.55e-05	0.000266	CcSEcCtD
Silodosin—Abdominal pain—Methotrexate—hematologic cancer	5.55e-05	0.000266	CcSEcCtD
Silodosin—Insomnia—Doxorubicin—hematologic cancer	5.49e-05	0.000263	CcSEcCtD
Silodosin—Gastrointestinal pain—Epirubicin—hematologic cancer	5.37e-05	0.000257	CcSEcCtD
Silodosin—Rash—Prednisone—hematologic cancer	5.29e-05	0.000253	CcSEcCtD
Silodosin—Dermatitis—Prednisone—hematologic cancer	5.29e-05	0.000253	CcSEcCtD
Silodosin—Headache—Prednisone—hematologic cancer	5.26e-05	0.000252	CcSEcCtD
Silodosin—Gastrointestinal disorder—Doxorubicin—hematologic cancer	5.24e-05	0.000251	CcSEcCtD
Silodosin—Urticaria—Epirubicin—hematologic cancer	5.21e-05	0.00025	CcSEcCtD
Silodosin—Abdominal pain—Epirubicin—hematologic cancer	5.19e-05	0.000249	CcSEcCtD
Silodosin—Asthenia—Methotrexate—hematologic cancer	5.03e-05	0.000241	CcSEcCtD
Silodosin—Nausea—Prednisone—hematologic cancer	4.99e-05	0.000239	CcSEcCtD
Silodosin—Gastrointestinal pain—Doxorubicin—hematologic cancer	4.97e-05	0.000238	CcSEcCtD
Silodosin—Pruritus—Methotrexate—hematologic cancer	4.96e-05	0.000238	CcSEcCtD
Silodosin—Urticaria—Doxorubicin—hematologic cancer	4.83e-05	0.000231	CcSEcCtD
Silodosin—Abdominal pain—Doxorubicin—hematologic cancer	4.8e-05	0.00023	CcSEcCtD
Silodosin—Diarrhoea—Methotrexate—hematologic cancer	4.8e-05	0.00023	CcSEcCtD
Silodosin—Asthenia—Epirubicin—hematologic cancer	4.71e-05	0.000226	CcSEcCtD
Silodosin—Pruritus—Epirubicin—hematologic cancer	4.64e-05	0.000222	CcSEcCtD
Silodosin—Dizziness—Methotrexate—hematologic cancer	4.64e-05	0.000222	CcSEcCtD
Silodosin—Diarrhoea—Epirubicin—hematologic cancer	4.49e-05	0.000215	CcSEcCtD
Silodosin—Rash—Methotrexate—hematologic cancer	4.42e-05	0.000212	CcSEcCtD
Silodosin—Dermatitis—Methotrexate—hematologic cancer	4.42e-05	0.000212	CcSEcCtD
Silodosin—Headache—Methotrexate—hematologic cancer	4.39e-05	0.00021	CcSEcCtD
Silodosin—Asthenia—Doxorubicin—hematologic cancer	4.36e-05	0.000209	CcSEcCtD
Silodosin—Dizziness—Epirubicin—hematologic cancer	4.34e-05	0.000208	CcSEcCtD
Silodosin—Pruritus—Doxorubicin—hematologic cancer	4.3e-05	0.000206	CcSEcCtD
Silodosin—Nausea—Methotrexate—hematologic cancer	4.17e-05	0.0002	CcSEcCtD
Silodosin—Diarrhoea—Doxorubicin—hematologic cancer	4.16e-05	0.000199	CcSEcCtD
Silodosin—Rash—Epirubicin—hematologic cancer	4.14e-05	0.000198	CcSEcCtD
Silodosin—Dermatitis—Epirubicin—hematologic cancer	4.14e-05	0.000198	CcSEcCtD
Silodosin—Headache—Epirubicin—hematologic cancer	4.11e-05	0.000197	CcSEcCtD
Silodosin—Dizziness—Doxorubicin—hematologic cancer	4.02e-05	0.000192	CcSEcCtD
Silodosin—Nausea—Epirubicin—hematologic cancer	3.9e-05	0.000187	CcSEcCtD
Silodosin—Rash—Doxorubicin—hematologic cancer	3.83e-05	0.000183	CcSEcCtD
Silodosin—Dermatitis—Doxorubicin—hematologic cancer	3.83e-05	0.000183	CcSEcCtD
Silodosin—Headache—Doxorubicin—hematologic cancer	3.81e-05	0.000182	CcSEcCtD
Silodosin—Nausea—Doxorubicin—hematologic cancer	3.61e-05	0.000173	CcSEcCtD
Silodosin—ABCB1—Transmembrane transport of small molecules—ALB—hematologic cancer	7.28e-06	7.39e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—CDKN2B—hematologic cancer	7.26e-06	7.37e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—FN1—hematologic cancer	7.25e-06	7.35e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling by GPCR—PIK3R1—hematologic cancer	7.19e-06	7.29e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—NFKBIA—hematologic cancer	7.16e-06	7.27e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—BAD—hematologic cancer	7.16e-06	7.27e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—CA9—hematologic cancer	7.1e-06	7.2e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—ACP5—hematologic cancer	7.1e-06	7.2e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—NOTCH1—hematologic cancer	7.09e-06	7.2e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—CD86—hematologic cancer	7.02e-06	7.12e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—NCOR2—hematologic cancer	7.01e-06	7.11e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling by GPCR—JAK2—hematologic cancer	6.99e-06	7.08e-05	CbGpPWpGaD
Silodosin—UGT2B7—Metabolism—PTEN—hematologic cancer	6.98e-06	7.08e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—CD80—hematologic cancer	6.95e-06	7.05e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—PIK3CG—hematologic cancer	6.94e-06	7.04e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—KIT—hematologic cancer	6.94e-06	7.04e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling by GPCR—NRAS—hematologic cancer	6.94e-06	7.04e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—HES1—hematologic cancer	6.93e-06	7.03e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—IL2RA—hematologic cancer	6.91e-06	7.01e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—NQO1—hematologic cancer	6.91e-06	7e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—CD44—hematologic cancer	6.91e-06	7e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—NCOR1—hematologic cancer	6.89e-06	6.99e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling by GPCR—IL2—hematologic cancer	6.86e-06	6.96e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—TERT—hematologic cancer	6.83e-06	6.93e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—PTPN11—hematologic cancer	6.82e-06	6.91e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—CSF2—hematologic cancer	6.81e-06	6.91e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—FGF1—hematologic cancer	6.81e-06	6.91e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—FOXO1—hematologic cancer	6.71e-06	6.81e-05	CbGpPWpGaD
Silodosin—ADRA1A—GPCR downstream signaling—IL2—hematologic cancer	6.71e-06	6.8e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—PDGFRB—hematologic cancer	6.7e-06	6.8e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—IDH1—hematologic cancer	6.68e-06	6.77e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—PDGFB—hematologic cancer	6.67e-06	6.77e-05	CbGpPWpGaD
Silodosin—UGT2B7—Metabolism—EP300—hematologic cancer	6.66e-06	6.75e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling by GPCR—MAPK3—hematologic cancer	6.64e-06	6.74e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling by GPCR—PIK3CB—hematologic cancer	6.63e-06	6.73e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—CREB1—hematologic cancer	6.6e-06	6.7e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—TXN—hematologic cancer	6.6e-06	6.7e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—ABCC3—hematologic cancer	6.6e-06	6.7e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—GSTO1—hematologic cancer	6.6e-06	6.7e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—PDGFRA—hematologic cancer	6.6e-06	6.69e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—PRKCG—hematologic cancer	6.57e-06	6.67e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—JAK1—hematologic cancer	6.57e-06	6.67e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—CYCS—hematologic cancer	6.53e-06	6.63e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—BRAF—hematologic cancer	6.52e-06	6.61e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—TSC2—hematologic cancer	6.52e-06	6.61e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—HSP90AA1—hematologic cancer	6.49e-06	6.58e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—CCL2—hematologic cancer	6.46e-06	6.55e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—SPHK1—hematologic cancer	6.46e-06	6.55e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—IL6R—hematologic cancer	6.44e-06	6.53e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—CREBBP—hematologic cancer	6.43e-06	6.52e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—FGFR3—hematologic cancer	6.27e-06	6.36e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—MAPK14—hematologic cancer	6.21e-06	6.3e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—UGT1A1—hematologic cancer	6.21e-06	6.3e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—IL2RA—hematologic cancer	6.14e-06	6.23e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—MAP2K1—hematologic cancer	6.14e-06	6.23e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—PIK3CD—hematologic cancer	6.1e-06	6.19e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling by GPCR—IL2—hematologic cancer	6.09e-06	6.18e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—ESR1—hematologic cancer	6.09e-06	6.18e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—TERT—hematologic cancer	6.07e-06	6.16e-05	CbGpPWpGaD
Silodosin—ADRA1D—GPCR downstream signaling—PIK3CA—hematologic cancer	6.04e-06	6.13e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—SLC22A1—hematologic cancer	6.04e-06	6.12e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—CRABP1—hematologic cancer	6.04e-06	6.12e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—FN1—hematologic cancer	6.02e-06	6.1e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling by GPCR—KRAS—hematologic cancer	5.97e-06	6.06e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—NFKBIA—hematologic cancer	5.95e-06	6.03e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—BAD—hematologic cancer	5.95e-06	6.03e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—PDGFB—hematologic cancer	5.93e-06	6.01e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—NOTCH1—hematologic cancer	5.89e-06	5.97e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—ALOX5—hematologic cancer	5.88e-06	5.97e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—FGF2—hematologic cancer	5.84e-06	5.92e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—TSC2—hematologic cancer	5.79e-06	5.87e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—CD80—hematologic cancer	5.77e-06	5.85e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—GSTP1—hematologic cancer	5.76e-06	5.84e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—PIK3R1—hematologic cancer	5.76e-06	5.84e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—KIT—hematologic cancer	5.76e-06	5.84e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—PIK3CG—hematologic cancer	5.76e-06	5.84e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling by GPCR—NRAS—hematologic cancer	5.76e-06	5.84e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—NUP98—hematologic cancer	5.7e-06	5.78e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—PTPN11—hematologic cancer	5.66e-06	5.74e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—JAK2—hematologic cancer	5.6e-06	5.68e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—FGFR3—hematologic cancer	5.57e-06	5.65e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—ADCY7—hematologic cancer	5.53e-06	5.61e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—NCOA3—hematologic cancer	5.53e-06	5.61e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—MAPK14—hematologic cancer	5.52e-06	5.59e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling by GPCR—MAPK3—hematologic cancer	5.51e-06	5.59e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—NUP214—hematologic cancer	5.49e-06	5.57e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling by GPCR—PIK3CA—hematologic cancer	5.49e-06	5.56e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—CREB1—hematologic cancer	5.48e-06	5.56e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—MDM2—hematologic cancer	5.46e-06	5.54e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—BRAF—hematologic cancer	5.41e-06	5.49e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—ESR1—hematologic cancer	5.41e-06	5.49e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—MTR—hematologic cancer	5.38e-06	5.46e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—ABCG2—hematologic cancer	5.38e-06	5.46e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—CCL2—hematologic cancer	5.36e-06	5.44e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—IL6R—hematologic cancer	5.35e-06	5.42e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—FN1—hematologic cancer	5.34e-06	5.42e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—CREBBP—hematologic cancer	5.34e-06	5.41e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—MTOR—hematologic cancer	5.32e-06	5.39e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—PIK3CB—hematologic cancer	5.32e-06	5.39e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—NCOR1—hematologic cancer	5.29e-06	5.37e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—GSTM1—hematologic cancer	5.29e-06	5.37e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—NFKBIA—hematologic cancer	5.28e-06	5.36e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—BAD—hematologic cancer	5.28e-06	5.36e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—ENO2—hematologic cancer	5.28e-06	5.35e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—NOTCH1—hematologic cancer	5.23e-06	5.3e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—CD80—hematologic cancer	5.12e-06	5.2e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—GSTT1—hematologic cancer	5.12e-06	5.19e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—PIK3CG—hematologic cancer	5.11e-06	5.19e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—KIT—hematologic cancer	5.11e-06	5.19e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling by GPCR—NRAS—hematologic cancer	5.11e-06	5.19e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—MAP2K1—hematologic cancer	5.1e-06	5.17e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling by GPCR—HRAS—hematologic cancer	5.08e-06	5.15e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—PIK3CD—hematologic cancer	5.06e-06	5.13e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—PTPN11—hematologic cancer	5.02e-06	5.1e-05	CbGpPWpGaD
Silodosin—ADRA1B—GPCR downstream signaling—PIK3CA—hematologic cancer	5.01e-06	5.09e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—SDC1—hematologic cancer	5e-06	5.07e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—CDKN1B—hematologic cancer	4.99e-06	5.06e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling by GPCR—KRAS—hematologic cancer	4.96e-06	5.03e-05	CbGpPWpGaD
Silodosin—ADRA1D—GPCR downstream signaling—AKT1—hematologic cancer	4.94e-06	5.01e-05	CbGpPWpGaD
Silodosin—UGT2B7—Metabolism—PIK3CA—hematologic cancer	4.92e-06	4.99e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling by GPCR—MAPK3—hematologic cancer	4.9e-06	4.97e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—CASP3—hematologic cancer	4.89e-06	4.96e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—IL2—hematologic cancer	4.88e-06	4.95e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—CREB1—hematologic cancer	4.87e-06	4.94e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling by GPCR—IL6—hematologic cancer	4.86e-06	4.93e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—FGF2—hematologic cancer	4.85e-06	4.92e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—BRAF—hematologic cancer	4.81e-06	4.88e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—PIK3R1—hematologic cancer	4.78e-06	4.85e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—CCL2—hematologic cancer	4.76e-06	4.83e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—CCND1—hematologic cancer	4.76e-06	4.83e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—IL6R—hematologic cancer	4.75e-06	4.82e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—JUN—hematologic cancer	4.75e-06	4.82e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—CREBBP—hematologic cancer	4.74e-06	4.81e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—MTHFR—hematologic cancer	4.68e-06	4.74e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—JAK2—hematologic cancer	4.65e-06	4.71e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—CDKN1A—hematologic cancer	4.6e-06	4.67e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—PTEN—hematologic cancer	4.59e-06	4.66e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling by GPCR—PIK3CA—hematologic cancer	4.55e-06	4.62e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—MDM2—hematologic cancer	4.53e-06	4.6e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—MAP2K1—hematologic cancer	4.53e-06	4.59e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—PIK3CD—hematologic cancer	4.5e-06	4.56e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—MAPK8—hematologic cancer	4.49e-06	4.56e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling by GPCR—AKT1—hematologic cancer	4.48e-06	4.55e-05	CbGpPWpGaD
Silodosin—ADRA1A—GPCR downstream signaling—PIK3CA—hematologic cancer	4.45e-06	4.52e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—MTOR—hematologic cancer	4.41e-06	4.47e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—PIK3CB—hematologic cancer	4.41e-06	4.47e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling by GPCR—KRAS—hematologic cancer	4.4e-06	4.46e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—EP300—hematologic cancer	4.38e-06	4.44e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—FGF2—hematologic cancer	4.31e-06	4.37e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—SRC—hematologic cancer	4.26e-06	4.32e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—NQO1—hematologic cancer	4.25e-06	4.32e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—CD44—hematologic cancer	4.25e-06	4.32e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—PIK3R1—hematologic cancer	4.25e-06	4.31e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling by GPCR—HRAS—hematologic cancer	4.21e-06	4.27e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—VEGFA—hematologic cancer	4.15e-06	4.21e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—CDKN1B—hematologic cancer	4.14e-06	4.2e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—JAK2—hematologic cancer	4.13e-06	4.19e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—STAT3—hematologic cancer	4.11e-06	4.17e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—NRAS—hematologic cancer	4.1e-06	4.16e-05	CbGpPWpGaD
Silodosin—ADRA1B—GPCR downstream signaling—AKT1—hematologic cancer	4.1e-06	4.15e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—CASP3—hematologic cancer	4.06e-06	4.12e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—IL2—hematologic cancer	4.05e-06	4.11e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling by GPCR—PIK3CA—hematologic cancer	4.04e-06	4.1e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling by GPCR—IL6—hematologic cancer	4.03e-06	4.09e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—MDM2—hematologic cancer	4.03e-06	4.09e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—CYCS—hematologic cancer	4.03e-06	4.08e-05	CbGpPWpGaD
Silodosin—UGT2B7—Metabolism—AKT1—hematologic cancer	4.02e-06	4.08e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	4e-06	4.06e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—CCND1—hematologic cancer	3.95e-06	4.01e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—JUN—hematologic cancer	3.94e-06	4e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—PIK3CG—hematologic cancer	3.93e-06	3.99e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—MAPK3—hematologic cancer	3.92e-06	3.98e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—MTOR—hematologic cancer	3.92e-06	3.97e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—PIK3CB—hematologic cancer	3.92e-06	3.97e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—CDKN1A—hematologic cancer	3.82e-06	3.88e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—MYC—hematologic cancer	3.82e-06	3.87e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—PTEN—hematologic cancer	3.81e-06	3.87e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—TGFB1—hematologic cancer	3.81e-06	3.86e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling by GPCR—HRAS—hematologic cancer	3.74e-06	3.79e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—MAPK8—hematologic cancer	3.73e-06	3.78e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling by GPCR—AKT1—hematologic cancer	3.72e-06	3.77e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—CDKN1B—hematologic cancer	3.68e-06	3.73e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—CREBBP—hematologic cancer	3.64e-06	3.7e-05	CbGpPWpGaD
Silodosin—ADRA1A—GPCR downstream signaling—AKT1—hematologic cancer	3.64e-06	3.69e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—EP300—hematologic cancer	3.64e-06	3.69e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—CASP3—hematologic cancer	3.6e-06	3.66e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—IL2—hematologic cancer	3.6e-06	3.65e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling by GPCR—IL6—hematologic cancer	3.58e-06	3.63e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—GSTP1—hematologic cancer	3.55e-06	3.6e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—SRC—hematologic cancer	3.54e-06	3.59e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—KRAS—hematologic cancer	3.53e-06	3.58e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—CCND1—hematologic cancer	3.51e-06	3.56e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—JUN—hematologic cancer	3.5e-06	3.55e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—PIK3CD—hematologic cancer	3.45e-06	3.5e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—VEGFA—hematologic cancer	3.44e-06	3.49e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—ALB—hematologic cancer	3.41e-06	3.46e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—STAT3—hematologic cancer	3.41e-06	3.46e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—NRAS—hematologic cancer	3.4e-06	3.45e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—CDKN1A—hematologic cancer	3.39e-06	3.44e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—PTEN—hematologic cancer	3.39e-06	3.43e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—ABCB1—hematologic cancer	3.36e-06	3.41e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—MAPK8—hematologic cancer	3.31e-06	3.36e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling by GPCR—AKT1—hematologic cancer	3.3e-06	3.35e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—PIK3R1—hematologic cancer	3.26e-06	3.31e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—NCOR1—hematologic cancer	3.26e-06	3.31e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—GSTM1—hematologic cancer	3.26e-06	3.31e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—MAPK3—hematologic cancer	3.26e-06	3.3e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—PIK3CA—hematologic cancer	3.24e-06	3.29e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—EP300—hematologic cancer	3.23e-06	3.28e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—MYC—hematologic cancer	3.17e-06	3.21e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—TGFB1—hematologic cancer	3.16e-06	3.21e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—SRC—hematologic cancer	3.14e-06	3.19e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—TP53—hematologic cancer	3.14e-06	3.18e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—VEGFA—hematologic cancer	3.06e-06	3.1e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—STAT3—hematologic cancer	3.03e-06	3.07e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—NRAS—hematologic cancer	3.02e-06	3.06e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—PIK3CB—hematologic cancer	3.01e-06	3.05e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—HRAS—hematologic cancer	3e-06	3.04e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—KRAS—hematologic cancer	2.93e-06	2.97e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—MAPK3—hematologic cancer	2.89e-06	2.93e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—MTHFR—hematologic cancer	2.88e-06	2.92e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—IL6—hematologic cancer	2.87e-06	2.91e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—MYC—hematologic cancer	2.81e-06	2.85e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—TGFB1—hematologic cancer	2.81e-06	2.85e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—PIK3CA—hematologic cancer	2.69e-06	2.73e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—AKT1—hematologic cancer	2.65e-06	2.69e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—PTEN—hematologic cancer	2.6e-06	2.64e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—TP53—hematologic cancer	2.6e-06	2.64e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—KRAS—hematologic cancer	2.6e-06	2.64e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—HRAS—hematologic cancer	2.49e-06	2.52e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—EP300—hematologic cancer	2.48e-06	2.52e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—PIK3CG—hematologic cancer	2.42e-06	2.46e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—PIK3CA—hematologic cancer	2.39e-06	2.42e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—IL6—hematologic cancer	2.38e-06	2.42e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—TP53—hematologic cancer	2.31e-06	2.34e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—CREBBP—hematologic cancer	2.24e-06	2.28e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—HRAS—hematologic cancer	2.21e-06	2.24e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—AKT1—hematologic cancer	2.2e-06	2.23e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—PIK3CD—hematologic cancer	2.13e-06	2.16e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—IL6—hematologic cancer	2.12e-06	2.15e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—ALB—hematologic cancer	2.1e-06	2.13e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—PIK3R1—hematologic cancer	2.01e-06	2.04e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—AKT1—hematologic cancer	1.95e-06	1.98e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—PIK3CB—hematologic cancer	1.86e-06	1.88e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—PIK3CA—hematologic cancer	1.84e-06	1.86e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—PTEN—hematologic cancer	1.6e-06	1.63e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—EP300—hematologic cancer	1.53e-06	1.55e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—AKT1—hematologic cancer	1.5e-06	1.52e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—PIK3CA—hematologic cancer	1.13e-06	1.15e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—AKT1—hematologic cancer	9.24e-07	9.37e-06	CbGpPWpGaD
